First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
Ce communiqué de presse est seulement disponible en anglais.
Do you want to stay updated about the press releases?